Stocktoria
Vanda Pharmaceuticals Inc. VNDA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2006-04-12
Vanda Pharmaceuticals Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -70.0% | -20.5% | -7.2% | 2.5% | 15.7% |
| Net margin | -102.0% | -9.5% | 1.3% | 2.5% | 12.3% |
| FCF margin | -51.1% | -8.2% | 6.4% | 12.3% | 23.7% |
| Return on assets | -45.1% | -2.9% | 0.4% | 1.0% | 5.6% |
| Return on equity | -67.4% | -3.5% | 0.5% | 1.2% | 6.6% |
| Current ratio | 2.39 | 4.39 | 4.94 | 5.68 | 6.43 |
| Revenue growth | 8.7% | 3.2% | -24.3% | -5.3% | 8.3% |
Source: SEC EDGAR filings · CIK 0001347178 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.